Cargando…

Health economic evidence for adjuvant chemotherapy in stage II and III colon cancer: a systematic review

OBJECTIVE: The aims of this study was to appraise the health economic evidence for adjuvant chemotherapy (AC) strategies in stage II and III colon cancer (CC) and identify gaps in the available evidence that might inform further research. METHOD: A systematic review of published economic evaluations...

Descripción completa

Detalles Bibliográficos
Autores principales:	To, Yat Hang, Gibbs, Peter, Tie, Jeanne, IJzerman, Maarten, Degeling, Koen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887815/ https://www.ncbi.nlm.nih.gov/pubmed/36721219 http://dx.doi.org/10.1186/s12962-023-00422-2

Ejemplares similares

Circulating Tumour DNA Guided Adjuvant Chemotherapy Decision Making in Stage II Colon Cancer—A Clinical Vignette Study
por: To, Yat Hang, et al.
Publicado: (2023)

Real-world evidence on adjuvant chemotherapy in older adults with stage II/III colon cancer
por: Batra, Atul, et al.
Publicado: (2020)

Adjuvant Chemotherapy for Stage III Colon Cancer
por: Taieb, Julien, et al.
Publicado: (2020)

Adjuvant Chemotherapy Benefit in Elderly Stage II/III Colon Cancer Patients
por: Chen, Xin, et al.
Publicado: (2022)

Health economic evidence for the use of molecular biomarker tests in hematological malignancies: A systematic review
por: Vu, Martin, et al.
Publicado: (2022)

Adjuvant Chemotherapy for Stage II Colon Cancer
por: Rebuzzi, Sara Elena, et al.
Publicado: (2020)

Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models
por: Degeling, Koen, et al.
Publicado: (2017)

Cost‐effectiveness of adjuvant chemotherapy for high‐risk stage II and stage III colon cancer in South Africa
por: Tan, Sarah Xinhui, et al.
Publicado: (2023)

Health Economic Evidence for Liquid- and Tissue-based Molecular Tests that Inform Decisions on Prostate Biopsies and Treatment of Localised Prostate Cancer: A Systematic Review
por: Degeling, Koen, et al.
Publicado: (2021)

Introduction to Metamodeling for Reducing Computational Burden of Advanced Analyses with Health Economic Models: A Structured Overview of Metamodeling Methods in a 6-Step Application Process
por: Degeling, Koen, et al.
Publicado: (2020)

Can we increase efficiency of CT lung cancer screening by combining with CVD and COPD screening? Results of an early economic evaluation
por: Behr, Carina M., et al.
Publicado: (2022)

Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
por: Hu, Huabin, et al.
Publicado: (2020)

Estimating the optimal rate of adjuvant chemotherapy utilization for stage III colon cancer
por: Karim, Safiya, et al.
Publicado: (2019)

Survival Outcomes of Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer
por: Khalil, Lana, et al.
Publicado: (2022)

High Expression of CUL9 Is Prognostic and Predictive for Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer
por: Zheng, Peng, et al.
Publicado: (2022)

Adjuvant chemotherapy for stage II colon cancer: who really needs it
por: Yang, Yan, et al.
Publicado: (2018)

The effect of smoking, obesity and diabetes on recurrence‐free and overall survival in patients with stage III colon cancer receiving adjuvant chemotherapy
por: Croese, Alex, et al.
Publicado: (2021)

Oncologic outcomes of early adjuvant chemotherapy initiation in patients with stage III colon cancer
por: Jeong, Woon Kyung, et al.
Publicado: (2015)

Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change?
por: Roda, Desamparados, et al.
Publicado: (2018)

Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients
por: Boakye, Daniel, et al.
Publicado: (2021)

A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer
por: Schippinger, W, et al.
Publicado: (2007)

Implementing competing risks in discrete event simulation: the event-specific probabilities and distributions approach
por: Franchini, Fanny, et al.
Publicado: (2023)

Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients
por: Morris, M, et al.
Publicado: (2007)

Adjuvant chemotherapy for stage III colon cancer: relative dose intensity and survival among veterans
por: Aspinall, Sherrie L, et al.
Publicado: (2015)

Stage III Colon Cancer: The Individualized Strategy of Adjuvant Chemotherapy for Aged Under and Over 70
por: Lu, Chieh-Sheng, et al.
Publicado: (2015)

Diabetes alone should not be a reason for withholding adjuvant chemotherapy for stage III colon cancer
por: van Waalwijk, Maren A., et al.
Publicado: (2011)

Immunoscore(®) as a predictor of response to chemotherapy in stage II and stage III colon cancer
por: Mlecnik, Bernhard, et al.
Publicado: (2015)

Towards Routine Implementation of Liquid Biopsies in Cancer Management: It Is Always Too Early, until Suddenly It Is Too Late
por: IJzerman, Maarten J., et al.
Publicado: (2021)

The value of adjuvant chemotherapy in stage II/III colorectal signet ring cell carcinoma
por: Zhao, Zhuang, et al.
Publicado: (2020)

S-1 as adjuvant chemotherapy for stage III colon cancer: a randomized phase III study (ACTS-CC trial)
por: Yoshida, M., et al.
Publicado: (2014)

Effectiveness of Adjuvant Chemotherapy with 5-FU/Leucovorin and Prognosis in Stage II Colon Cancer
por: Jee, Sun Hee, et al.
Publicado: (2011)

Effect of Adjuvant Chemotherapy on Stage II Colon Cancer: Analysis of Korean National Data
por: Kim, Min Ki, et al.
Publicado: (2018)

Stroma-normalised vessel density predicts benefit from adjuvant fluorouracil-based chemotherapy in patients with stage II/III colon cancer
por: Mezheyeuski, Artur, et al.
Publicado: (2019)

Adjuvant chemotherapy in stage II and III colon cancer: the role of the “budding and TILs-(tumor-infiltrating lymphocytes) combination” as tumor-host antagonists
por: Lang-Schwarz, Corinna, et al.
Publicado: (2021)

Adjuvant chemotherapy for patients with stage II high-risk and III colon cancer: Hindering factors to adherence and impact on long-term survival
por: Kim, Jieun, et al.
Publicado: (2021)

Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study
por: Gao, Peng, et al.
Publicado: (2018)

Stratification of Stage III colon cancer may identify a patient group not requiring adjuvant chemotherapy
por: Malik, Yasir G., et al.
Publicado: (2020)

Modeling the Cost-Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer in South African Public Hospitals
por: Pumpalova, Yoanna, et al.
Publicado: (2021)

Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.
por: Saarto, T., et al.
Publicado: (1997)

Irregular delay of adjuvant chemotherapy correlated with poor outcome in stage II-III colorectal cancer
por: Chen, Yuanyuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_m88vakco67uf1dfaqcmh7o4g88